TTOO: T2 Biosystems EV/EBITDA Multiple

T2 Biosystems, Inc. (TTOO) develops innovative devices for rapid blood sepsis analysis, utilizing the proprietary T2MR method to bypass slow laboratory tests, while its US-based manufacturing capacities ensure the deployment of these systems in intensive care units. This chart of the share price on GURU.Markets reflects an EV/EBITDA of . Current revenue is based on equipment sales, while growth potential is embedded in future government defense contracts.

T2 Biosystems Inc - TTOO Enterprise Value to EBITDA Ratio (period 07/04/2022 - 11/11/2026)

Summary analytical data breakdowns for t2biosystems.com (TTOO)

- stock price and consensus target price:

Stock Quotes T2 Biosystems, Inc|TTOO - Analyst Forecast Prices

- market capitalization information:

Market Capitalization T2 Biosystems Inc|TTOO - Company Buyout Price

- issuer book value statistics:

Book Value per Share T2 Biosystems|TTOO - Company Net Assets|Market Cap to Net Assets Ratio t2biosystems.com|TTOO - Aggregate Asset Value

- company liabilities and liquidity data:

- financial results and valuation multiples details:

TTOO - Net Income|Projected Future Earnings T2 Biosystems, Inc.|TTOO - P/E Multiple|Future Price to Earnings T2 Biosystems, Inc.|TTOO - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio T2 Biosystems Inc|TTOO - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) T2 Biosystems|TTOO - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months t2biosystems.com|TTOO - Net earnings per share change in current year|Expected earnings per share growth for next year T2 Biosystems, Inc.

Initial company analysis:T2 Biosystems, Inc TTOO

The EV/EBITDA ratio determines the value of a company, including net debt, relative to its operating profit, allowing for an assessment of the asset's payback period excluding taxes and depreciation. By analyzing the historical EV/EBITDA ratio of a business, an investor identifies the extent of the overpayment for the asset and the issuer's level of financial discipline. For T2 Biosystems, Inc. (TTOO), this metric confirms business resilience, as sepsis diagnostics are not subject to market cycles or crises.

Competitor analysis for T2 Biosystems, Inc.

Abbott Laboratories Inc. - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio TMO (Thermo Scientific)|GE HealthCare - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio mt.com MTD|WAT: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Bio-Techne Corp|Enterprise Value to EBITDA Ratio BRKR|AZTA: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Varex Imaging (VREX)|Enterprise Value to EBITDA Ratio semlerscientific.com SMLR|EV/EBITDA Multiple BFLY (Butterfly Network)|Mesa Laboratories Inc (MLAB) - Company Value to EBITDA|Quantum-Si Corp - EV/EBITDA Multiple|NNOX (Nano-X Imaging Ltd) - Enterprise Value to Operating Income Before Depreciation|QTRX: EV/EBITDA Multiple|MASS - Total Company Value to Operating Income Before Depreciation Ratio|CV (CapsoVision, Inc.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio MaxCyte Inc. (MXCT)|EV/EBITDA Multiple RPID|EV/EBITDA Multiple Seer Bio (SEER)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Hyperfine, Inc. HYPR|fonar.com - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|DXR: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation MDAI (spectral-ai.com)|VIVS: EV/EBITDA Multiple|Company Value to EBITDA Aclarion Corporation (ACON)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Akoya Biosciences Inc|THMO - Enterprise Value to EBITDA Multiple|Enterprise Value to EBITDA Ratio TLIS (Talis Biomedical)